Premarket Submissions
Strategic, practitioner-led 510(k) preparation that anticipates FDA reviewer questions before they become deficiency letters — reducing clearance time and avoiding costly back-and-forth.
Schedule a Free Discovery CallWhat We Do
The most common reason 510(k)s fail isn't poor technical writing — it's poor strategy upstream. Device classification errors, weak predicate selection, and misaligned testing programs create problems that surface as AI/AR cycles, or worse, a Not Substantially Equivalent (NSE) determination.
ADB CRO approaches every 510(k) with a structured front-end analysis before any documentation begins. We identify the right product code, confirm device classification under 21 CFR, evaluate multiple potential predicates against your device's intended use and technological characteristics, and flag the testing and labeling requirements specific to your device type. This work — often underestimated — is what separates a first-round clearance from a nine-month deficiency cycle.
Predicate strategy is the core of every 510(k). FDA's substantial equivalence standard requires that your device have the same intended use as the predicate and either the same technological characteristics or technological differences that do not raise new safety and effectiveness questions. Selecting a predicate that's too dissimilar forces you to justify every difference; selecting one that's too old means citing a device with outdated performance standards.
We conduct systematic predicate searches using the FDA 510(k) database, 21 CFR classification regulations, and product codes. For complex devices, we evaluate split-predicate strategies — using one predicate for intended use and another for technological characteristics — and assess the risks of that approach. Where the predicate landscape is unclear, we recommend a Pre-Submission meeting before committing to a filing strategy.
Testing gaps are the leading cause of 510(k) deficiency letters. FDA reviewers use device-specific guidance documents, recognized consensus standards (ASTM, ISO, IEC), and their own reviewer guidance to benchmark what testing they expect to see. We know these expectations by device type — and we build your testing strategy to match.
For software-enabled devices, this includes cybersecurity documentation (per FDA's 2023 cybersecurity guidance), software documentation per FDA's Software as a Medical Device guidance (IEC 62304 compliance, hazard analysis, V&V testing), and — where applicable — AI/ML considerations under the 2021 action plan. For electromechanical devices, we coordinate biocompatibility testing (ISO 10993 series), electrical safety (IEC 60601), and performance testing against recognized standards.
Even well-prepared 510(k)s receive Additional Information (AI) or Deficiency (AR) requests. How you respond determines whether the review stays on track or enters a prolonged multi-cycle process. We manage all FDA correspondence — drafting substantive responses that directly address each reviewer concern, supplementing with additional test data where necessary, and maintaining the administrative record that supports your response.
510(k) preparation typically takes 3–6 months, depending on device complexity and testing requirements. FDA review adds another 3–12 months. Total time from kickoff to clearance is commonly 9–18 months for a well-prepared submission.
Substantial equivalence means your device has the same intended use as the predicate and either the same technological characteristics, or different characteristics that do not raise new safety and effectiveness questions. It is the legal standard 510(k) clearance is based on.
Most Class II devices and some Class I devices require a 510(k) before marketing. Whether your specific device requires one depends on its classification under 21 CFR Parts 862–892 and whether an exemption applies. We determine this as the first step of every engagement.
Get Started
Tell us your device, your predicate candidates, and your target market entry date. We'll tell you exactly what we'd do — and what risks we see — in the first call.